Disclosure Mike Kirby has received funding for research, conference attendance, lecturing and advice from the pharmaceutical industry including, Pfizer, MSD, GSK, Astellas, Bayer, Lilly and Takeda.
Chris Chapple has worked as a consultant to American Medical Systems and Lilly, as a consultant and researcher to ONO, as a consultant, researcher and speaker for Allergan, Astellas, Pfizer and Recordati.
Graham Jackson has advised Lilly, Pfizer and Bayer, and talked at sponsored educational meetings.
Ian Eardley has worked as a consultant and speaker for Lilly, Bayer, Pfizer and Allergan.
David Edwards has received funding for research, lecturing, advisory board and conference attendance from the pharmaceutical industry including Bayer, GSK, Lilly, Pfizer, ProStakan and Owen Mumford.
Geoff Hackett is an occasional speaker and advisory board member for Lilly and Bayer.
Jon Rees has worked as a consultant to Lilly, GSK and Pfizer, and has received speaker funding from GSK & Lilly.
David Ralph has worked as a consultant to Lilly, Axillium, Coloplast and American Medical Systems. Mark Speakman has received research funding from Allergan, Astellas, GSK and Genprobe. He has been a lecturer for Astellas, GSK, Lilly and Genprobe.
Julian Spinks has worked as a consultant to Pfizer, GSK, Astellas Orion and Boehringer Ingelheim, and received speaker fees from Pfizer and Astellas.
Kevan Wylie has no conflicts of interest.
Consensus statement: Evidence suggests a strong link between erectile dysfunction and lower urinary tract symptoms in men that is independent of age. Co-diagnosis of these conditions is therefore important.
Despite differences in design, many large epidemiological studies using well-powered multivariate analyses consistently provide overwhelming evidence of a link between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS). Preclinical evidence suggests that several common pathophysiological mechanisms are involved in the development of both ED and LUTS. We recommend that patients seeking consultation for one condition should always be screened for the other condition. We propose that co-diagnosis would ensure that patient management accounts for all possible co-morbid and associated conditions. Medical, socio-demographic and lifestyle risk factors can help to inform diagnoses and should be taken into consideration during the initial consultation. Awareness of risk factors may alert physicians to patients at risk of ED or LUTS and so allow them to manage patients accordingly; early diagnosis of ED in patients with LUTS, for example, could help reduce the risk of subsequent cardiovascular disease. Prescribing physicians should be aware of the sexual adverse effects of many treatments currently recommended for LUTS; sexual function should be evaluated prior to commencement of treatment, and monitored throughout treatment to ensure that the choice of drug is appropriate.
Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) occur frequently as men age. Both conditions have common pathogenetic mechanisms and epidemiological data support a link between ED and LUTS in men that is independent of age and other co-morbidities.
For all men presenting with either ED or LUTS, co-diagnosis of the other condition should be considered. Men should be asked about their sexual or urinary health, as appropriate, and other possible co-morbid conditions should also be investigated. Recognition of the link between ED and LUTS, and further links with other co-morbid conditions, will improve patient and partner quality of life as well as reducing patient morbidity and mortality.
Erectile dysfunction (ED), defined as the inability to maintain and achieve an erection for satisfactory intercourse , has a high prevalence and incidence worldwide. A systematic review of epidemiological evidence undertaken in 2002  showed a clear linear increase in prevalence with advancing age, with rates for men younger than 40 years ranging from approximately 2–9%, compared with 18–86% for those older than 80 years. In the Cologne Male Survey , overall prevalence of ED was 19.2% with a steep age-related increase from 2% in the 30–39 years age group to 53% in the 70–80 years age group. In the UrEpik study , overall prevalence of ED was 21% with a statistically significant linear increase with age (p < 0.001). Although ED is not life threatening, it may be a precursor of more serious conditions, particularly coronary artery disease (CAD). Inman et al.  have shown that when ED occurs in younger men, it is associated with a marked increase in the risk of future cardiac events and that overall ED may be associated with an approximately 80% higher risk of subsequent CAD.
Lower urinary tract symptoms (LUTS) in men are caused by a group of disorders affecting the prostate and bladder that share a similar clinical manifestation. National Institute of Health and Clinical Excellence (NICE) guidelines define LUTS as comprising storage, voiding and postmicturition symptoms affecting the lower urinary tract . Voiding symptoms include weak or intermittent urinary stream, straining, hesitancy, terminal dribbling and incomplete emptying. Storage symptoms include urgency, increased frequency, urgency incontinence and nocturia. The major postmicturition symptom is postmicturition dribbling, which is common and bothersome. Although LUTS do not usually cause severe illness, they can considerably reduce men's quality of life, and may point to serious pathology of the urogenital tract . Storage LUTS are often more prevalent and more bothersome than voiding LUTS [7, 8] and are often related to underlying bladder dysfunction that may be secondary to benign prostatic enlargement (BPE), or may arise because of other factors affecting bladder physiology . Clinicians should consider all possible causes of LUTS prior to treatment: These include problems with fluid intake, medical conditions such as diabetes or heart failure, and other urological conditions such as overactive bladder or urethral stricture. However, the most common association of male LUTS is BPE secondary to benign prostatic hyperplasia (BPH)1 . The prevalence of BPH increases with age and approximately 25–50% of men with BPH have LUTS . In a large retrospective cohort study of 80,774 males who contributed 141,035 person-years of follow-up, the overall incidence rate of LUTS/BPH was 15 per 1000 man-years (95% CI: 14.8–16.1). The incidence increased linearly with age to a maximum of 38 patients per 1000 at the age of 75–79 years (95% CI: 34.1–42.9) . Other studies have shown that LUTS can occur in 15–60% of men older than 40 years of age [12-15], and bothersome LUTS can occur in up to 30% of men older than 65 years . Although figures differ from study to study as a result of different definitions and data collected, LUTS are experienced by a large number of men potentially requiring treatment; this figure will continue to rise with increasing life expectancy and the resulting growth of the elderly population .
Preservation of sexual function is an important component of quality of life and needs to be considered sympathetically as part of the management of male patients . In general, both ED and LUTS affect sexual function and hence quality of life. An international study, designed to examine men's attitudes and behaviours in relation to their ED, emphasised the importance of the couple relationship, and strengthened the view that ED may matter to men because of its significant impact on valued partner relationships . This point is illustrated by results from a multinational epidemiological study of female partners of men with ED, which showed a significant decline in desire, arousal, orgasm and satisfaction following the onset of ED . Results from the large EpiLUTS study found that sexual enjoyment declined and sexual activity decreased with increasing LUTS; of the 2954 respondents reporting a combination of voiding, storage and postmicturition symptoms at least sometimes, 28.8% said that their sexual enjoyment was ‘somewhat’, ‘quite a bit’ or ‘a great deal’ decreased because of LUTS, and 24.8% had decreased or stopped sexual activity because of LUTS . The multinational UrEpik study  investigated the impact of LUTS on quality of life and showed that the presence of LUTS in a patient also had an adverse effect on quality of life for the partner. In a later study, results were similar; Mitropoulus et al.  studied more than 50 couples in which the male partner suffered from LUTS and showed that all partners suffered with some reduction in quality of life that was directly related to this condition. The most common morbidities were related to the psychological burden of the condition, inadequate sex life, disruption of social life and sleep disturbance. Sells et al.  developed a disease-specific questionnaire to assess morbidity in the partners of patients with LUTS and as a result were able to confirm the presence of significant morbidity; almost all partners experienced some morbidity as a consequence of the patients’ conditions, with the most common issues being sleep disturbance, fear of cancer and surgery, social disruption and deterioration in sex life.
There is considerable evidence that LUTS and sexual dysfunction are strongly linked (Table 1). Recognition of these links can be important because:
Table 1. Epidemiological evidence from community studies (ranked by sample size)
Relevant results for an association between ED and LUTS
ED, erectile dysfunction; LUTS, lower urinary tract symptoms; BPH, benign prostatic hyperplasia; EJD, ejaculatory dysfunction; PE, painful ejaculation; CI, confidence interval; IPSS, International Prostate Symptoms Score; IIEF, International Index of Erectile Function; COPD, chronic obstructive pulmonary disease.
Sexual disorders and ‘bothersomeness’ were strongly related to both age and severity of LUTS. When controlling for age, LUTS severity was by far the strongest predictor of ED, with an odds ratio for severe versus mild LUTS of 8.90 (6.85–11.55)
The presence of LUTS was an independent risk factor for the presence of ED; in multivariate analysis controlling for age, co-morbidities and lifestyle, the IPSS (p = 0.0001), the obstructive score of the IPSS (p = 0.0001), nocturia (p = 0.04), and the LUTS bother score (p = 0.002) correlated with the presence of ED (IIEF-5 score < 22)
ED was significantly associated with LUTS, nocturia and prostatitis in bivariate associations, and with prostatitis in multivariate analyses, controlling for the effects of diabetes and other co-morbidities
Sexual disorders increased with age and increasing severity of LUTS. Erectile problems were present in 33%, 61% and 87% of men with no or mild LUTS aged 50–59, 60–69 and 70–80 years, respectively, and in 54%, 84% and 91% of men with moderate to severe LUTS
The prevalence of moderate to severe ED (IIEF-5 < 12) was significantly associated with LUTS severity (p < 0.05). A consistent inverse correlation was found between IIEF-5 and IPSS severity across the age groups, with the strongest effect observed in patients aged 60–69 years (p < 0.01)
Overall IPSS scores were significantly associated with ED (p = 0.002) and there was an association between the severity of ED and LUTS (p = 0.008). Logistic regression analyses showed that IPSS scores and ED remained independently associated even after controlling for confounding factors (p = 0.01)
In the severe LUTS patient group, IIEF erectile function domain scores were significantly lower than in the moderate LUTS patient group (p < 0.05). Multiple logistic regression analysis confirmed that presence of ED was the most significant predictor of severe LUTS
The second question in the IIEF-5 questionnaire (How would you rate your ability to have an erection hard enough for penetration?) showed a significant correlation with total IPSS score (p = 0.022). The sum of the IPSS obstructive symptoms scores showed a significant correlation with ED scores (p < 0.001)
Significant correlation between the IPSS and the SHIM (p < 0.001)
They improve understanding of the aetiology of the conditions.
They enable patients to connect conditions and risk factors.
They can inform case finding and screening strategies.
They can identify co-morbidities.
They can affect the choice of appropriate treatment.
Despite the wealth of literature in support of a link between ED and LUTS, there appears to be a lack of awareness of this link in both primary and secondary care, which manifests itself in underuse of appropriate diagnostic tools  or prescribed drugs . For example, in a UK audit of 100 patients with LUTS, GPs enquired about ED in < 10% and offered no therapy to more than 80% of those with ED, yet 91% of untreated ED patients said they would like medical treatment . A brief survey of the services used to inform GPs in the UK shows that although the possibility of a link may be mentioned, no recommendations on co-diagnosis are given; for example, in clinical IT systems such as WebMentor, there is no mention of ED or sexual function in LUTS information for doctors and no mention of LUTS in the ED information. Similarly, in the recent NICE LUTS guidelines, although there is a mention of the association with ED, there are no constructive recommendations about how to ask about or manage any ED issues: ‘Men with lower urinary tract symptoms (LUTS) should have access to care that can help with their emotional and physical conditions and with relevant physical, psychological, sexual and social issues’ . In the LUTS ‘Map of Medicine’, there is a mention about enquiring about sexual function, but no mention of LUTS in the ED map . Several factors may reduce the likelihood of physicians asking about sexual function such as lack of time, embarrassment and insufficient knowledge on sexual health , but the most likely reason for failure to ask about ED in LUTS (and vice versa) is lack of awareness of the link between the two conditions.
Reasons why enquiries about sexual function may not be made:
lack of time
lack of confidence
respecting patient's privacy
difficulty in knowing how to ask
conservative sexual beliefs
insufficient knowledge on sexual health
insufficient acceptance of patient's special sexual profile
The aim of this publication was to raise awareness of the link between ED and LUTS for the purposes of possible co-diagnosis. We present a summary of the evidence for a link between ED and LUTS and highlight the need to consider both conditions together during the diagnostic process.
Evidence in support of a link between ED and LUTS
Despite the differences in design, many large studies using well-powered multivariate analyses consistently provide overwhelming evidence of a link between ED and LUTS.
There is a wealth of published data in support of a link between ED and LUTS; Table 1 outlines the main results from larger published studies although it is not intended as a comprehensive list. Several reviews have also published tabulations of selected epidemiological studies that support the existence of a link between ED and LUTS that is independent of age or co-morbidities [26-29].
In some of the larger studies that have evaluated relative risk or odds ratios of the probability of a link, the results clearly highlight the association between the two conditions. For example, in the large multinational survey of the ageing male (MSAM-7) , multivariate analysis showed that severity of LUTS was a strong predictor of sexual dysfunction, with an odds ratio for erection problems of 8.90 (95% CI: 6.85–11.55) in those with severe LUTS. Indeed, results from this important study essentially showed that going from mild to moderate, or moderate to severe LUTS, had a greater impact on ED than ageing by 10 years (Figure 1). Similarly, in a study involving patients in UK general practices , odds ratios for ED in patients with both storage and voidance LUTS were calculated to be 4.0 (95% CI: 3.4–4.8). From the ED perspective, a study in Finland involving over a 1000 men  calculated the relative risk of LUTS in patients with severe ED as 2.3 (95% CI: 1.4–3.8). In addition to these individual studies, a recent systematic review of available epidemiological data has concluded that most men seeking treatment for either LUTS or ED have both conditions . Taken together, these results provide overwhelming evidence of the independent association between LUTS and ED and highlight the importance of awareness of this link for the practising physician.
Current preclinical evidence suggests that several common pathogenetic mechanisms are involved in the development of both ED and LUTS associated with BPH.
The pathogenetic mechanisms underlying the relationship between LUTS and ED have been the subject of several recent reviews [27-29, 33]. These publications present preclinical data and well-defined theories for mechanisms currently thought to be involved, including, alteration of the nitric oxide-cyclic guanosine monophosphate pathway; enhancement of RhoA–Rho-kinase (ROCK) signalling; autonomic hyperactivity; and pelvic atherosclerosis. Additional contributing factors such as chronic inflammation  and sex steroid ratio imbalance may also play a role . Knowledge of the common pathways linking these mechanisms should allow a better understanding of the pathophysiology of both conditions .
The need for co-diagnosis
Given the strong evidence from multiple epidemiological studies that ED and LUTS are correlated, independent of age or co-morbidities (Table 1), we recommend that patients seeking consultation for one condition should always be screened for complaints about the other condition.
We propose that co-diagnosis could follow the algorithm given in Figure 3; this would then ensure that patient management accounts for all possible associated conditions.
Medical, demographic and lifestyle risk factors can help to inform diagnoses and should be taken into consideration during the initial consultation.
Awareness of risk factors may alert physicians to patients at risk of ED or LUTS and allow them to diagnose and manage both conditions appropriately.
ED is associated with increased all-cause mortality principally because of mortality from cardiovascular disease (CVD) ; early diagnosis of ED in patients with LUTS could help reduce the risk of subsequent CVD.
Some LUTS in men are associated with increased all-cause mortality; in particular, older men with nocturia have an increased likelihood of CVD and mortality even after adjusting for age, body mass index and urological medications . Early diagnosis and management of LUTS in a patient with ED could help reduce the risk of subsequent CVD and associated early death.
Physicians confronted with a patient with ED and/or LUTS should consider the possibility that the patient may also have type 2 diabetes mellitus (T2DM), hypertension, dyslipidaemia, other aspects of the metabolic syndrome or hypogonadism, and vice versa.
Several risk factors are associated with sexual dysfunction in men, including, age, individual general health status, sedentary lifestyle, depression, insomnia and other psychiatric/psychological disorders, diabetes mellitus, hypertension and CVD, hyperlipidaemia, other genitourinary disease, socio-demographic conditions and pelvic surgery [2, 30, 36, 38, 39]. A recent population-based cohort study of more than 3000 older men (75–95 years, mean 82 years) from Perth, Western Australia, showed that CVD, diabetes, depression, prostate disorders and insomnia were the factors most commonly associated with sexual problems in this cohort of older men . Importantly, diagnosis of ED can be predictive of CAD, with a time interval for CAD risk reduction of 2–5 years [36, 41]. As a result, identification of ED, particularly in men < 60 years old and in those with diabetes, can be a critical first step towards cardiovascular risk detection and reduction .
Several risk factors are associated with LUTS in men, including, age, BPE, hypogonadism, sedentary lifestyle, depression, hypertension and CVD, hyperlipidaemia, diabetes, obesity and inflammation [10, 11, 30, 43-45]. A recent retrospective cohort study has suggested that the use of statins may delay the development of LUTS by reducing inflammation and BPE . The study showed that statin use was associated with a 6.5–7 year delay in the new onset of moderate to severe LUTS or BPE.
More recently, ED and LUTS have been included in the list of factors associated with metabolic syndrome ; specifically, waist circumference has been significantly and positively associated with prostate volume, serum prostate-specific antigen and international prostate symptoms score . Higher waist circumferences have also been significantly associated with a greater prevalence of hypertension, CAD, T2DM and obesity, as well as the presence of ED and ejaculatory dysfunction . Metabolic syndrome is defined by a cluster of findings that directly increase the risk of CVD and T2DM. The main components are dyslipidaemia, hypertension and dysregulated glucose homeostasis, but central obesity (waist circumference) and/or insulin resistance are receiving increasing attention as the core manifestations of the syndrome . Other abnormalities such as chronic pro-inflammatory and pro-thrombotic states, non-alcoholic fatty liver disease and sleep apnoea have also recently been added to the spectrum, making the definition of metabolic syndrome even more complex . The most relevant current definition incorporates the International Diabetes Federation (IDF) and American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) definitions and requires a patient to have any three of the following conditions .2
Elevated waist circumference (ethnicity specific values, e.g. for European males > 94 cm and females > 80 cm).
Triglycerides 1.7 mmol/l or greater (> 50 mg/dl).
HDL-cholesterol below 1.03 mmol/l (< 40 mg/dl) in males and below 1.29 mmol/l (< 50 mg/dl) in females.
BP 130/85 mmHg or greater.
Fasting glucose 5.6 mmol/l or greater (> 100 mg/dl).
Prescribing physicians should be aware of the sexual adverse effects of treatments for LUTS; by thinking about co-diagnosis of ED, sexual function will be fully evaluated prior to commencement of treatment and monitored throughout to ensure that the choice of drug treatment is appropriate.
Physicians should make patients aware of the potential sexual adverse effects of some treatments prior to prescribing; this may be of particular relevance in younger patients.
Physicians should also assess co-morbidities, concomitant medications and lifestyle to consider all associated risk factors and manage accordingly.
Many therapies recommended for the treatment of LUTS can affect sexual function and there are known cases of effects such as loss of libido, ED and ejaculatory disorders (Table 3) [27, 50]. The alpha(1)-blockers alfuzosin, doxazosin and terazosin appear to be associated with fewer sexual adverse effects than the alpha(1)-blocker tamsulosin or 5-alpha-reductase inhibitors, and alpha(1)-blocker plus 5-alpha-reductase inhibitor combination therapy . The newer alpha-blocker, silodosin may be associated with a higher incidence of sexual side effects than other drugs in the same class; a recent clinical trial investigating the effects of silodosin therapy for LUTS in men with suspected BPH–LUTS reported the percentage of subjects reporting ‘retrograde ejaculation’ was 14.2% in the silodosin group, which was significantly higher than the 2.1% and 1.1% in the tamsulosin and placebo treatment groups, respectively . Combination therapy is likely to increase the risk of sexual adverse effects , for example, in the MTOPS study (Medical Therapy of Prostatic Symptoms) , ED was volunteered as a side effect in 5.8% of patients treated with the combination of finasteride and doxazosin, a higher proportion than seen with either agent alone. However, it is worth noting that there was no baseline assessment of sexual function in this study and as a result, these data could be misleading.
Table 3. Sexual adverse events associated with drugs used in the treatment for BPH–LUTS reported from clinical trials (Adapted from Refs [50, 52])
Taken from Chapple . Treatment-emergent adverse events. Data from pooled results of two phase III, 12-week studies. Drug-related adverse events reported in year 1 of study. EJD includes decreased ejaculate volume and ejaculation disorder; ED reported as ‘impotence’. ED, erectile dysfunction; EJD, ejaculatory dysfunction; retrograde ejaculation, orgasm with no semen, orgasm semen quantity reduced, and retrograde ejaculation.
Although adverse events data from clinical trials can give an estimation of the risk of these events, it is important to tailor treatment and management individually; the incidence of adverse effects reported in clinical trials does not necessarily represent real-life experience and assessed adverse events are not necessarily representative of patient-volunteered side effects.
Many men with LUTS and/or ED will also have other health problems and may be receiving treatment with drugs that have associated sexual adverse events; for example, many antihypertensive drugs such as the diuretics can cause ED . Other classes of drugs that can cause sexual adverse effects include antipsychotic agents , antidepressants , beta-blockers , antihistamines, Parkinson's disease medications and muscle relaxants [50, 56].
Attention to lifestyle modifications such as weight loss, increased physical activity and decreased use of recreational drugs including alcohol is also important, because recent research has suggested that lifestyle and metabolic factors are significantly associated with increased risks of LUTS . Factors associated with decreased risks include increased physical activity, moderate alcohol intake and increased vegetable consumption .
Potential situations in which to refer to secondary care
Most patients with LUTS and ED can be managed by the primary care physician. Situations in which specialist assessment may be required are outlined in current guidelines [6, 59]. Generally, referral will only be necessary for patients who fail to respond to initial treatment or where there are complications.
Most patients with LUTS, ED or both conditions are suitable for initial management in primary care; because these patients often have co-morbid conditions such as CVD or diabetes; the primary care physician is perfectly placed to initiate holistic assessment and management. Possible exceptions include those in whom a phosphodiesterase-5 (PDE-5) inhibitor is contraindicated, for example, when a patient has complex cardiovascular co-morbidity. Otherwise, referral need only take place for those patients who fail to respond to initial medical management in primary care or who have complications as outlined in recent guideline statements , or when the physician is concerned and needs further support.
Specialist assessment can be undertaken by physicians working in secondary care, or those in primary care with specialist expertise and ability for this kind of evaluation . NICE guidelines for LUTS recommend specialist referral when patients have bothersome LUTS that have not responded to conservative management or drug treatment, or if they have LUTS complicated by recurrent or persistent urinary tract infection, retention, renal impairment that is suspected to be caused by lower urinary tract dysfunction, or suspected urological cancer . Additional trigger points that may suggest a need for review or specialist referral include macroscopic haematuria, deterioration in kidney function or an unexplained, clinically significant increase in postvoid residual urine volume .
Current guidelines for ED in older men suggest referral be considered for men with a history of trauma (e.g. to the genital area, pelvis or spine), for men who do not respond to at least two different PDE-5 inhibitors at the maximum tolerated dose, or who have hypogonadism . All men with ED should have their cardiovascular risk assessed in primary care and addressed appropriately. Men with symptoms of CVD that restrict their ability to exercise need further evaluation to establish the safety of sexual activity and ED treatment. Men in their 40s and 50s who are at increased risk of cardiac events, whether cardiac symptoms are present or not, should be considered for more detailed cardiac evaluation [36, 41].
Referral to secondary care should be considered when:
There is an indication for surgery
There is a complex cardiovascular co-morbidity
There is no response to conservative management or drug treatment
There is evidence of worsening on drug treatment
There is a history of trauma or abnormalities of the penis or testes
The diagnosis is complicated by symptoms that are suggestive of:
Recurrent or persistent urinary tract infection
Chronic urinary retention*
Lower urinary tract disease, bladder or prostate** cancer
*Postvoid residual volume should be quantified when incomplete bladder emptying is suspected; although there is no consensus and considerable controversy surrounding what constitutes a diagnosis of retention, a postvoid residual volume of > 300 ml is generally agreed to suggest retention 
**PSA testing can be offered at the physician's discretion if symptoms are suggestive of benign prostate enlargement, the prostate feels abnormal, or the patient or physician is concerned about prostate cancer
Erectile dysfunction and LUTS are conditions with both high prevalence and significant negative impact on patients' quality of life. There is a strong epidemiological evidence for a link between ED and LUTS supported by theories for their shared pathogenesis.
Although physicians are aware of LUTS and ED, knowledge that there are links between the two is often lacking. This leads to missed opportunities to diagnose and treat these conditions and to consider potential serious co-morbidities. As LUTS and ED have complex multifactorial aetiologies and multiple associations, including, diabetes, lipid disorders, metabolic syndrome and major cardiac diseases, they provide an important opportunity for interdisciplinary care and for primary care physicians to work closely with urologists, cardiologists, endocrinologists and physicians caring for elderly people.
When seeing patients with either LUTS or ED, the routine approach should be to ask about symptoms of both conditions at first contact. The management of LUTS and ED is as much about managing their associations as the prescribing of effective medication; many risk factors are shared and these need to be assessed and addressed to treat the patient holistically. For example, early diagnosis of ED in a patient presenting with LUTS and modification of any risk factors wherever possible could reduce the likelihood or delay the onset of subsequent CVD. There is clear evidence that effective treatment for one condition can improve the other, but only by assessing the co-morbidities for both conditions can therapy be tailored to achieve the desired outcome for the patient and his partner. The ability to treat both LUTS and ED together with one medication and lifestyle advice is worthy of consideration.
Mike Kirby: discussion leader and consensus co-ordinator, contribution of data and critical revisions to manuscript.
Chris Chapple and Graham Jackson: involvement in concept and article development, critical appraisal of content and contribution of data to the content.
Ian Eardley, David Edwards, Geoff Hackett, David Ralph, Jon Rees, Mark Speakman, Julian Spinks and Kevan Wylie: involvement in drafting the article, critical appraisal of content and contribution of data to the content.
Eli Lilly and Company (Lilly) has provided the financial support for the medical writing assistance for the preparation of this article. Some of the authors have served as paid consultants in a medical advisory board organised by Lilly on related subject matter. The authors would like to acknowledge Clare Gurton and Rx Communications for their medical writing assistance.
‘Benign prostatic hyperplasia’ should be reserved for histopathologically confirmed hyperplastic changes (i.e. abnormality/changes at the cell level) in the prostate (NICE 2010).
The IDF/AHA/NHLBI definition is given in US units, these have been converted to UK units for the purposes of this publication with the US units in brackets. In some cases, the individual values that are part of this overall definition of metabolic syndrome are a little lower than those accepted in other individual diagnoses.